Skip to main content
. 2020 Jun 23;20:179. doi: 10.1186/s12890-020-01187-7

Table 1.

Histological findings in H&E-stained tissue specimens of CD-1 mice intratracheally treated with different doses of SPA4 peptide (n = 11–15 mice per group)

Group Histological findings
0.625 μg SPA4 peptide/g body weight (n = 12)

Normal-appearing lung (n = 11/12), spleen (n = 12/12), intestine (n = 12/12), kidney (n = 12/12), heart (n = 12/12), and liver (n = 12/12).

Lung tissue from one mouse revealed moderate congestion and edema with a mixed inflammatory cell infiltrate involving both the terminal and conducting airways, consistent with a moderate diffuse subacute bronchopneumonia.

1.25 μg SPA4 peptide/g body weight (n = 13)

Normal-appearing lung (n = 13/13), spleen (n = 13/13), intestine (n = 13/13), kidney (n = 13/13), heart (n = 13/13), and liver (n = 12/13).

Liver from one mouse revealed a mild to moderate infiltrate of mostly lymphocytes within the periportal zones consistent with moderate chronic multifocal hepato-cholangitis.

2.5 μg SPA4 peptide/g body weight (n = 13)

Normal-appearing lung (n = 13/13), spleen (n = 13/13), intestine (n = 13/13), kidney (n = 13/13), heart (n = 13/13), and liver (n = 12/13).

Liver from one mouse revealed increased mitotic activity.

5 μg SPA4 peptide/g body weight (n = 11)

Normal-appearing lung (n = 11/11), spleen (n = 11/11), intestine (n = 11/11), kidney (n = 11/11), heart (n = 11/11), and liver (n = 10/11).

Liver tissue from one mouse revealed mild to moderate infiltration of mostly lymphocytes within the periportal zones consistent with moderate chronic multifocal hepato-cholangitis.

10 μg SPA4 peptide/g body weight (n = 12) Normal-appearing lung (n = 12/12), spleen (n = 12/12), intestine (n = 12/12), kidney (n = 12/12), heart (n = 12/12), and liver (n = 12/12).
Vehicle control (n = 11)

Normal-appearing lung (n = 11/11), spleen (n = 11/11), intestine (n = 11/11), kidney (n = 10/11), heart (n = 11/11), and liver (n = 11/11).

The kidney in one mouse revealed a small subcapsular foci of tubular loss with several small foci of chronic interstitial inflammation.

Untreated control (n = 15) Normal-appearing lung (n = 15/15), spleen (n = 15/15), intestine (n = 15/15), kidney (n = 15/15), heart (n = 15/15), and liver (n = 15/15).